Chronic graft versus host disease is a serious complication that can develop after an allogeneic stem cell transplant, when donor cells begin to attack the recipient’s organs and tissues. Treatment depends on which body parts are affected and how severe the symptoms are, with approaches ranging from topical remedies to powerful immune-suppressing medications and newer therapies being tested in clinical trials.

Treatment Goals and Personalized Approaches

When someone develops chronic graft versus host disease (cGVHD) after receiving donor stem cells, the main goal of treatment is to calm down the immune system so that the donor cells stop attacking the patient’s body. This is different from fighting cancer directly – instead, doctors work to reduce inflammation, prevent tissue scarring, and help patients maintain as much normal function and quality of life as possible while their body adjusts to the donor cells.^[1]

Treatment plans for chronic GVHD are highly individualized because the disease affects people in very different ways. Some patients develop mild symptoms in just one organ, while others experience severe problems affecting their skin, mouth, eyes, liver, lungs, digestive system, joints, or genitals. The intensity of treatment depends not only on which organs are involved but also on how much the symptoms interfere with daily activities and whether the patient has other health conditions that might complicate therapy.^[3]

Unlike acute GVHD, which typically appears within the first 100 days after transplant, chronic GVHD can develop at any time, though most cases emerge within the first two years. This longer timeline means patients need to remain vigilant even after they’ve passed the early recovery period and returned home from frequent hospital visits. The disease can last for varying periods – many people see gradual improvement over a few months, but treatment often continues for three to five years, and in rare cases, some patients require lifelong immunosuppressive therapy (medications that reduce immune system activity).^[5]

The treatment approach also considers whether someone previously had acute GVHD, their age, the type of donor they had (related versus unrelated, how closely matched the donor’s tissue type was), and whether they’re still recovering from other transplant-related complications. All these factors help doctors predict how the disease might progress and which treatments are most likely to help.^[3]

Standard Treatment Methods

For patients whose chronic GVHD affects only one or two organs and causes relatively mild symptoms, doctors often start with localized treatments rather than medications that affect the whole body. These might include skin ointments or creams for rashes, eye drops for dry or irritated eyes, or mouth rinses for oral symptoms. This approach minimizes side effects while still providing relief for the specific problem areas.^[3]

When chronic GVHD is more widespread or severe, or when localized treatments aren’t working well enough, doctors prescribe systemic medications that work throughout the entire body. Corticosteroids, particularly prednisone, remain the cornerstone of initial treatment for patients requiring systemic therapy. These powerful anti-inflammatory drugs help reduce the immune system’s attack on body tissues. Prednisone is often the first medication doctors reach for when someone is newly diagnosed with chronic GVHD that needs more than topical care.^[7]

Corticosteroids work by dampening the overall immune response, which helps reduce inflammation and tissue damage throughout the body. However, these medications come with significant challenges when used long-term. Patients taking corticosteroids may experience mood swings, difficulty sleeping, increased appetite and weight gain, high blood sugar levels, weakened bones (osteoporosis), increased risk of infections, muscle weakness, and changes in appearance such as a rounded face or easy bruising. Because of these side effects, doctors try to use the lowest effective dose and gradually reduce the amount as symptoms improve.^[7]

For many patients, prednisone is combined with other immunosuppressive medications to improve effectiveness while potentially allowing lower steroid doses. Common partners include cyclosporine (or its newer relative tacrolimus), which work by inhibiting T lymphocytes – the immune cells primarily responsible for the graft-versus-host reaction. Another medication called sirolimus works through a different mechanism but also helps calm the immune response. Mycophenolate mofetil is another option that blocks immune cell multiplication.^[3]

A specialized procedure called extracorporeal photopheresis offers an alternative for some patients, especially those who haven’t responded well to medications or who need to reduce their steroid dose due to side effects. During this treatment, blood is removed from the patient, white blood cells are separated out, exposed to ultraviolet light, and then returned to the body. The UV-treated cells seem to help regulate the immune system in beneficial ways. This approach is particularly useful for chronic GVHD affecting the skin, though it requires regular visits to a treatment center for sessions that can take several hours.^[3]

The duration of standard treatment varies widely depending on how well symptoms respond and how severe the GVHD was at the start. Most patients require treatment for at least several months to a few years. The goal is always to gradually reduce medications once symptoms improve, but this must be done carefully to avoid triggering a flare-up of GVHD. Some patients can eventually stop all treatment, while others need to continue low doses of medication for longer periods to keep symptoms under control.^[5]

When Standard Treatment Isn’t Enough

A significant challenge in managing chronic GVHD is that not all patients respond adequately to corticosteroids and traditional immunosuppressive drugs. This situation, called steroid-refractory chronic GVHD, occurs when symptoms don’t improve despite proper treatment with corticosteroids, or when the disease worsens even while taking these medications. Other patients develop steroid-dependent GVHD, meaning they need such high doses of corticosteroids to control symptoms that the side effects become unbearable or dangerous.^[7]

For these difficult cases, doctors have historically tried various other immunosuppressive medications, though evidence for their effectiveness came mainly from smaller studies and experiences at individual transplant centers rather than from large, rigorous clinical trials. Treatment strategies varied considerably between hospitals, and there was no clear consensus on the best approach for patients who didn’t respond to standard therapy.^[7]

This landscape has changed dramatically in recent years, particularly in the last decade, which has witnessed perhaps the greatest advances in chronic GVHD treatment since transplantation began. Three novel medications have now received approval from regulatory authorities for treating chronic GVHD in patients who haven’t responded adequately to steroids or who need alternatives to standard therapy. These represent the first drugs specifically approved for this indication, offering hope and better options for patients with difficult-to-treat disease.^[9]

Innovative Treatments Being Tested in Clinical Trials

Ibrutinib, marketed under the brand name Imbruvica, became the first medication specifically approved for chronic GVHD when it received authorization in 2017. This drug works by blocking an enzyme called Bruton’s tyrosine kinase (BTK), which plays an important role in the signaling pathways that activate immune cells involved in the graft-versus-host reaction. By inhibiting this enzyme, ibrutinib helps reduce the abnormal immune response driving chronic GVHD.^[5]

The approval of ibrutinib was based on results from an open-label Phase I/II clinical trial that included adults with chronic GVHD who had previously received at least one line of systemic therapy without adequate improvement. The trial showed that ibrutinib produced meaningful responses in many patients, with improvements seen across multiple organ systems including the skin, mouth, liver, and gastrointestinal tract. Patients also reported improvements in their quality of life, which is a crucial outcome given how much chronic GVHD can interfere with daily activities and wellbeing.^[9]

Ruxolitinib, sold as Jakafi, received approval as another treatment option for steroid-refractory chronic GVHD. This medication works as a JAK inhibitor – it blocks enzymes called Janus kinases (JAK1 and JAK2) that are involved in signaling pathways related to inflammation and immune activation. By interrupting these signals, ruxolitinib helps dampen the immune system’s attack on the patient’s tissues.^[8]

The clinical trials testing ruxolitinib included patients aged 12 years and older who had chronic GVHD that had failed to respond adequately to corticosteroids. The studies demonstrated that ruxolitinib could produce responses in patients whose disease had proven resistant to other treatments. This medication is taken orally as a pill, making it convenient for long-term use at home. The approval extended to both adults and adolescents, recognizing that chronic GVHD can affect younger transplant recipients as well.^[4]

Belumosudil, marketed as Rezurock, represents a third approved option with a different mechanism of action. This drug works by inhibiting an enzyme called ROCK2 (Rho-associated coiled-coil kinase 2), which is involved in multiple processes that contribute to chronic GVHD, including inflammation, tissue scarring (fibrosis), and abnormal immune responses. By targeting ROCK2, belumosudil may help address not just the inflammatory aspects of chronic GVHD but also the fibrotic changes that can cause lasting tissue damage and disability.^[8]

The availability of these three different medications – each working through distinct biological mechanisms – gives doctors and patients options for personalizing treatment. If one medication doesn’t work well or causes intolerable side effects for a particular patient, switching to another agent with a different mechanism might prove more successful. Treatment selection can be based on the patient’s individual needs, which organs are affected, other medical conditions they have, and their tolerance for potential side effects.^[8]

Research into new treatments for chronic GVHD continues at transplant centers around the world, including locations in the United States, Europe, and other regions. Clinical trials are investigating additional novel agents and treatment approaches for patients who don’t respond to currently available therapies or who achieve only partial responses. These studies span different phases of clinical research.^[8]

Phase I trials focus primarily on safety, testing new drugs in small groups of patients to determine appropriate doses and identify potential side effects. Phase II trials enroll more patients to evaluate whether the treatment shows evidence of effectiveness against chronic GVHD and to gather more information about side effects. Phase III trials are large studies that compare new treatments against current standard therapies to determine whether the new approach offers advantages in terms of effectiveness, safety, or quality of life.^[8]

Some trials are exploring whether combining different medications with complementary mechanisms might produce better results than using single agents. Others investigate whether starting newer agents earlier in the disease course – rather than waiting until standard treatments have failed – might prevent progression to severe, difficult-to-treat chronic GVHD. Researchers are also studying ways to identify which patients are most likely to benefit from specific treatments, using biological markers that might predict response.^[8]

Eligibility for clinical trials varies depending on the specific study, but generally includes patients who have been diagnosed with chronic GVHD according to established criteria, have received previous treatment (often at least one or two prior therapies) without adequate response, and meet certain health requirements to ensure they can safely participate. Some trials have restrictions based on age, the severity of organ involvement, or the presence of other medical conditions. Patients interested in clinical trials should discuss options with their transplant team, who can help identify appropriate studies and provide referrals.^[8]

Most Common Treatment Methods

• Corticosteroids (Systemic Immunosuppression)
  • Prednisone as first-line therapy for patients requiring systemic treatment
  • Often combined with other immunosuppressive agents like cyclosporine, tacrolimus, or sirolimus
  • Mycophenolate mofetil used as an additional immunosuppressive option
  • Treatment typically lasts from several months to several years, with gradual dose reduction as symptoms improve
• Localized Therapies
  • Topical ointments and creams for skin manifestations
  • Eye drops for dry and irritated eyes
  • Mouth rinses for oral symptoms
  • Used when chronic GVHD affects only one or two organs with mild symptoms
• Extracorporeal Photopheresis
  • Blood cells removed, exposed to ultraviolet light, and returned to the body
  • Particularly useful for skin manifestations of chronic GVHD
  • Option for patients who haven’t responded to medications or need to reduce steroid doses
  • Requires regular treatment center visits for multi-hour sessions
• Targeted Therapy (BTK Inhibitors)
  • Ibrutinib (Imbruvica) – first FDA-approved medication specifically for chronic GVHD
  • Blocks Bruton’s tyrosine kinase enzyme involved in immune cell activation
  • Approved for adults with steroid-refractory chronic GVHD
  • Oral medication taken at home
• Targeted Therapy (JAK Inhibitors)
  • Ruxolitinib (Jakafi) – blocks JAK1 and JAK2 enzymes
  • Approved for patients aged 12 years and older with steroid-refractory chronic GVHD
  • Helps dampen inflammation and immune activation
  • Oral medication for convenient long-term use
• Targeted Therapy (ROCK2 Inhibitors)
  • Belumosudil (Rezurock) – inhibits ROCK2 enzyme
  • Addresses inflammation, fibrosis, and abnormal immune responses
  • Approved for steroid-refractory chronic GVHD
  • May help prevent lasting tissue damage from scarring
• Low-Dose Interleukin-2
  • Used in some cases of treatment-resistant chronic GVHD
  • Helps modulate immune system function
• Biological Agents
  • Abatacept – investigated for chronic GVHD management
  • Works through immune modulation pathways

Comprehensive Care and Quality of Life

Living with chronic GVHD often requires care from multiple medical specialists beyond the transplant team. Because the disease can affect so many different organs and tissues, patients frequently need coordinated care from dermatologists for skin problems, ophthalmologists for eye issues, gastroenterologists for digestive symptoms, pulmonologists for lung complications, and other specialists depending on which organs are involved. A multidisciplinary team approach that brings together these different experts helps ensure comprehensive management of all aspects of the disease.^[8]

The physical challenges of chronic GVHD are accompanied by significant emotional and psychological impacts. After enduring the stress of cancer treatment, transplant preparation, the transplant procedure itself, and early recovery, being diagnosed with chronic GVHD can feel overwhelming and discouraging. Many patients experience depression, anxiety, mood swings, and difficulty coping with the uncertainty of not knowing whether symptoms will improve, worsen, or how long treatment will be needed.^[10]

Chronic GVHD symptoms themselves can contribute to emotional distress. Physical changes from skin problems, hair loss, or weight changes may affect self-esteem and body image. Joint and muscle involvement can limit mobility and independence. Fatigue is common and can be profound, making it difficult to maintain work, social activities, and family responsibilities. Some medications used to treat chronic GVHD, particularly corticosteroids, can cause mood changes, sleep problems, and confusion, adding to the emotional burden.^[11]

Talking about these feelings with healthcare providers is important, as they can offer support and interventions. Many transplant centers have social workers, psychologists, or psychiatrists experienced in working with transplant patients and chronic GVHD survivors. Professional counseling can help patients process difficult emotions, develop coping strategies, and adjust to the changes chronic GVHD has brought to their lives. Some patients find medications for anxiety or depression helpful during particularly difficult periods.^[10]

Connecting with others who have experienced chronic GVHD can provide unique support that even the best medical team cannot replicate. Talking with someone who truly understands what living with chronic GVHD is like – because they’ve been through it themselves – can reduce feelings of isolation and provide practical tips for managing symptoms and treatment side effects. Many organizations offer peer support programs that connect chronic GVHD patients with survivors, as well as support groups where patients can share experiences and strategies.^[10]

Patients and caregivers often describe managing chronic GVHD as similar to having a full-time job. The disease brings challenges with physical functioning, fatigue, general health, social activities, and psychological wellbeing. Some of the effects of chronic GVHD – particularly tissue thickening, scarring, and fibrosis – can resemble symptoms of certain autoimmune diseases where the body’s immune system mistakenly attacks healthy organs.^[13]

Quality of life considerations should be central to treatment decisions. While controlling the disease is important, the goal is not just to suppress chronic GVHD at any cost but to achieve symptom control in a way that allows patients to maintain meaningful activities, relationships, and the best possible daily functioning. This sometimes means accepting some residual symptoms rather than pursuing more aggressive treatment with severe side effects. The “right” balance is individual and should be determined through open discussions between patients and their medical teams.^[14]

Practical coping strategies can help patients manage the stress and uncertainty of living with chronic GVHD. These include taking each day as it comes rather than trying to predict or control an unpredictable future, focusing on abilities rather than limitations, building flexibility into plans since symptoms can vary from day to day, noticing and appreciating small things that bring pleasure or joy, and engaging in non-medical activities that provide a sense of normalcy and remind patients of their identity beyond being a transplant recipient with GVHD.^[10]

Relaxation techniques, meditation, guided imagery, and mindfulness practices help many patients cope with the physical and emotional challenges of chronic GVHD. These approaches can reduce stress, improve sleep, help manage pain, and provide a sense of greater control during a situation that often feels uncontrollable. Some patients benefit from gentle exercise programs tailored to their abilities, which can help maintain mobility, reduce joint stiffness, improve mood, and counter some medication side effects like muscle weakness.^[10]

The caregivers of people with chronic GVHD also face significant challenges and stress. They often provide extensive physical care, help manage complex medication schedules, accompany patients to frequent medical appointments, and provide emotional support while dealing with their own worries and fatigue. Support services should extend to caregivers as well, recognizing their crucial role and the toll that caregiving takes on their own health and wellbeing.^[10]